Earnings Highlights
EPS Actual
-0.58
EPS Estimate
-0.72
Revenue Actual
Revenue Estimate
***
Stock Chat Room- Discover stronger investing opportunities with free access to breakout stock alerts, momentum indicators, and expert market commentary. Kiora Pharmaceuticals reported a Q1 2026 net loss of $0.58 per share, beating analyst estimates of a $0.7242 loss for a positive surprise of 19.91%. The company reported no revenue during the quarter, consistent with its pre-commercial stage. Despite the better-than-expected bottom line, shares declined 4.48% in the following session, reflecting ongoing investor focus on pipeline milestones and cash burn.